^
Association details:
Biomarker:FGFR3 fusion
Cancer:Urothelial Cancer
Drug:vofatamab (B-701) (FGFR3 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

Published date:
05/16/2018
Excerpt:
B-701 combined with standard dose D in an every 3 week schedule in patients with mUCC was well-tolerated with expected myelosuppression. Enhanced activity was seen in the FGFR3 M/F compared to WT patients
Secondary therapy:
docetaxel
DOI:
10.1200/JCO.2018.36.15_suppl.4534
Trial ID: